-
公开(公告)号:US07592308B2
公开(公告)日:2009-09-22
申请号:US11526225
申请日:2006-09-25
申请人: Michael John Dawson , Jesus Cortes Bargallo , Antony Nicholas Appleyard , Brian Arthur Michael Rudd , Steven Boakes , Gabriele Bierbaum , Anja Hoffmann , Stephanie Schmitz
发明人: Michael John Dawson , Jesus Cortes Bargallo , Antony Nicholas Appleyard , Brian Arthur Michael Rudd , Steven Boakes , Gabriele Bierbaum , Anja Hoffmann , Stephanie Schmitz
IPC分类号: A61K38/00
摘要: The present invention relates to methods and products for improved production of the lantibiotic mersacidin. There is provided a method of producing a mersacidin variant which comprises introducing into a cell which is a ΔMrsA host cell an expression vector encoding said variant, and recovering said variant from the cell culture. Preferred variants include the novel variants of Table 1, e.g. mersacidin F3W, said mersacidin F3W optionally having a further one or more variations, e.g. mersacidin F3W G8A. Also provided is a Bacillus cell which is a SigH deficient strain of Bacillus sp. HIL Y-85,54728 (NCIMB Accession Number NCIMB 41211); this cell may also be used in the production of mersacidin and its variants. Further aspects of the invention include a DNA cassette which comprises a nucleotide sequence encoding the mersacidin mrsA propeptide, and a method to transform a Bacillus HIL host cell with plasmid, which method includes the step of electroporation.
摘要翻译: 本发明涉及用于改善羊毛硫抗生素美沙芬生产的方法和产品。 提供了一种制备美沙西汀变体的方法,其包括将作为DeltaMrsA宿主细胞的细胞引入编码所述变体的表达载体,并从细胞培养物中回收所述变体。 优选的变体包括表1的新变体,例如。 美沙虫素F3W,所述美沙奎芬F3W可选地具有另外一个或多个变体,例如, mersacidin F3W G8A。 还提供了作为芽孢杆菌属SigH缺陷型菌株的芽孢杆菌细胞。 HIL Y-85,54728(NCIMB登录号NCIMB 41211); 该细胞也可以用于制备美沙沙坦及其变体。 本发明的其它方面包括含有编码美沙肽mrsA前肽的核苷酸序列的DNA盒,以及用质粒转化芽孢杆菌HIL宿主细胞的方法,该方法包括电穿孔步骤。
-
公开(公告)号:US20120302728A1
公开(公告)日:2012-11-29
申请号:US13576882
申请日:2011-02-01
申请人: Michael John Dawson , Antony Nicholas Appleyard , Jesus Cortes Bargallo , Sjoerd Nicolaas Wadman
发明人: Michael John Dawson , Antony Nicholas Appleyard , Jesus Cortes Bargallo , Sjoerd Nicolaas Wadman
IPC分类号: C07K7/54
摘要: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.
摘要翻译: 描述了基于羊毛硫抗生素的化合物,包含其的药物组合物和化合物和所述组合物的用途,用于治疗微生物感染,例如艰难梭菌(Clostridium difficile)或藤黄微球菌感染(Micrococcus luteus infection)。 基于羊毛硫素的化合物具有抗微生物活性,并且与一个或多个阿格达肽,阿那加丁B,脱氧基甘露糖B和脱氧维甲酸相比具有保留活性或改善的活性。
-
公开(公告)号:US09006392B2
公开(公告)日:2015-04-14
申请号:US13576882
申请日:2011-02-01
申请人: Michael John Dawson , Antony Nicholas Appleyard , Jesus Cortes Bargallo , Sjoerd Nicolaas Wadman
发明人: Michael John Dawson , Antony Nicholas Appleyard , Jesus Cortes Bargallo , Sjoerd Nicolaas Wadman
摘要: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.
摘要翻译: 描述了基于羊毛硫抗生素的化合物,包含其的药物组合物和化合物和所述组合物的用途,用于治疗微生物感染,例如艰难梭菌(Clostridium difficile)或藤黄微球菌感染(Micrococcus luteus infection)。 基于羊毛硫素的化合物具有抗微生物活性,并且与一个或多个阿格达肽,阿那加丁B,脱氧基甘露糖B和脱氧维甲酸相比具有保留活性或改善的活性。
-
公开(公告)号:US20120309676A1
公开(公告)日:2012-12-06
申请号:US13576892
申请日:2011-02-01
摘要: Described are certain salts of certain lantibiotic compounds, pharmaceutical compositions comprising the same and use of the salts and compositions for the treatment of microbial infection, particularly Methicillin-resistant Staphylococcus aureus (MRSA) infection. The salts have an aqueous solubility of 2.5 mg/mL or more.
摘要翻译: 描述了某些羊毛硫抗生素化合物的某些盐,包含其的药物组合物以及用于治疗微生物感染的盐和组合物的用途,特别是耐甲氧西林金黄色葡萄球菌(MRSA)感染。 盐的水溶解度为2.5mg / mL以上。
-
公开(公告)号:US20130171252A1
公开(公告)日:2013-07-04
申请号:US13810162
申请日:2011-07-12
IPC分类号: A61K38/12
CPC分类号: A61K38/12 , A61K9/4825 , A61K38/10
摘要: Described is a pharmaceutical formulation of a capsule for oral delivery of a type B lantibiotic to the stomach comprising a hard gelatine, HPMC or starch capsule, and a type B lantibiotic of formula (I): wherein X is —NH(CH2)qNH2 and q is an integer 2 to 12.
摘要翻译: 描述了用于将包含硬明胶,HPMC或淀粉胶囊的B型蓝霉素类型的口服递送至胃的胶囊和式(I)的B型蓝霉素的药物制剂:其中X是-NH(CH 2)q NH 2和 q为2〜12的整数。
-
公开(公告)号:US09192569B2
公开(公告)日:2015-11-24
申请号:US13816063
申请日:2011-08-09
CPC分类号: A61K9/0019 , A61K9/19 , A61K38/164 , A61K47/26
摘要: A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection is described, the formulation being clear of visual particulates and comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol and optionally a buffer.
摘要翻译: 描述了用于输注或直接注射的B型蓝霉素的液体胶体药物制剂,所述制剂不含视觉颗粒,并且包含B型蓝霉素或其盐,包含糖醇和任选的缓冲液的等渗水溶液。
-
公开(公告)号:US20130137630A1
公开(公告)日:2013-05-30
申请号:US13816063
申请日:2011-08-09
IPC分类号: A61K9/00
CPC分类号: A61K9/0019 , A61K9/19 , A61K38/164 , A61K47/26
摘要: Described is a A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol such as glycerol and/or a saccharide and optionally a buffer, wherein said final formulation for infusion or direct injection is clear of visual particulates.
摘要翻译: 描述了用于输注或直接注射的B型蓝霉素的A液体胶体药物制剂,其包含B型蓝霉素或其盐,包含糖醇如甘油和/或糖和任选的缓冲剂的等渗水溶液,其中 所述用于输注或直接注射的最终制剂不含视觉颗粒物。
-
-
-
-
-
-